Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;41(7):2225-2231.
doi: 10.1007/s10067-022-06113-2. Epub 2022 Feb 21.

Tofacitinib combined with leflunomide for treatment of psoriatic arthritis with IgA nephropathy: a case report with literature review

Huifang Xue #  1 , Xin Ci #  2 , Manyu Luo  1 , Lijun Wu  1 , Xinru Du  1 , Lin Li  1 , Xuehong Lu  3
Affiliations
Review

Tofacitinib combined with leflunomide for treatment of psoriatic arthritis with IgA nephropathy: a case report with literature review

Huifang Xue et al. Clin Rheumatol. 2022 Jul.

Abstract

Psoriasis is a systemic inflammatory disease that is associated with increased risk of several diseases, such as psoriatic arthritis (PsA), inflammatory bowel disease, and cardiovascular diseases. About 20 to 30% patients with psoriasis subsequently develop PsA. IgA nephropathy is the most common primary glomerular disease world-wide. Psoriasis and IgA nephropathy appear to be associated, but the mechanism underlying this connection is unclear. Tofacitinib and leflunomide are common treatments for psoriatic arthritis. We administered tofacitinib combined with leflunomide to a 38-year-old female patient who presented with PsA and IgA nephropathy. After treatment, she experienced significant reductions in the psoriatic lesions, pain in the right knee joint, and proteinuria. Administration of tofacitinib combined with leflunomide for treatment of a patient who had PsA complicated with IgA nephropathy led to significant resolution of the symptoms of both conditions. These results suggest similarities in the pathogenesis of PsA and IgA nephropathy and a possible new treatment for IgA nephropathy.

Keywords: IgA nephropathy; Janus kinase; Leflunomide; Psoriatic arthritis; Tofacitinib.

PubMed Disclaimer

References

    1. Kaushik SB, Lebwohl MG (2019) Psoriasis: which therapy for which patient psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 80:27–40 - DOI
    1. Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D et al (2019) Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 80:251–65.e19 - DOI
    1. Grewal SK, Wan J, Denburg MR, Shin DB, Takeshita J, Gelfand JM (2017) The risk of IgA nephropathy and glomerular disease in patients with psoriasis: a population-based cohort study. Br J Dermatol 176:1366–1369 - DOI
    1. Barratt J, Eitner F, Feehally J, Floege J (2009) Immune complex formation in IgA nephropathy: a case of the ‘right’ antibodies in the ‘wrong’ place at the ‘wrong’ time? Nephrol Dial Transpl 24:3620–3623 - DOI
    1. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673 - DOI

LinkOut - more resources